As of 2025-07-15, the Intrinsic Value of Iovance Biotherapeutics Inc (IOVA) is 15.34 USD. This IOVA valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 2.01 USD, the upside of Iovance Biotherapeutics Inc is 663.10%.
The range of the Intrinsic Value is 10.62 - 17.46 USD
Based on its market price of 2.01 USD and our intrinsic valuation, Iovance Biotherapeutics Inc (IOVA) is undervalued by 663.10%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (134.03) - (37.47) | (56.30) | -2901.2% |
| DCF (Growth 10y) | (31.19) - (95.05) | (43.82) | -2280.0% |
| DCF (EBITDA 5y) | 10.62 - 17.46 | 15.34 | 663.1% |
| DCF (EBITDA 10y) | 7.14 - 17.82 | 13.65 | 579.1% |
| Fair Value | -5.62 - -5.62 | -5.62 | -379.62% |
| P/E | (16.01) - (21.94) | (16.19) | -905.3% |
| EV/EBITDA | (13.60) - (13.28) | (16.58) | -924.7% |
| EPV | (17.67) - (25.28) | (21.47) | -1168.2% |
| DDM - Stable | (12.61) - (67.01) | (39.81) | -2080.6% |
| DDM - Multi | (10.11) - (42.56) | (16.43) | -917.3% |
| Market Cap (mil) | 671.20 |
| Beta | 1.59 |
| Outstanding shares (mil) | 333.93 |
| Enterprise Value (mil) | 500.53 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.87% |
| Cost of Debt | 5.00% |
| WACC | 7.87% |